



(51) International Patent Classification:

A61B 5/00 (2006.01) A61B 5/024 (2006.01)  
A61B 5/021 (2006.01) A61B 5/08 (2006.01)

(21) International Application Number:

PCT/US2018/033166

(22) International Filing Date:

17 May 2018 (17.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/508,442 19 May 2017 (19.05.2017) US

(71) Applicant: **CARDIAC PACEMAKERS, INC.** [US/US];  
4100 Hamline Avenue North, ST. PAUL, Minnesota 55112 (US).

(72) Inventors: **SHERWOOD, Gregory J.**; 18 Wildflower Place, NORTH OAKS, Minnesota 55127 (US). **SRIVASTAVA, Kyle Harish**; 590 Laurel Ave, SAINT PAUL, Minnesota 55102 (US). **CLARK, Bryan Allen**; 7600 North Shore Circle N, FOREST LAKE, Minnesota 55025 (US). **NELSON, Justin Theodore**; #510, 3820 Grand Way, ST. LOUIS PARK, Minnesota 55416 (US). **BAUER, Carl**

Walter; Apt. 5, 908 Ashland Ave, ST. PAUL, Minnesota 55104 (US).

(74) Agent: **DEFFNER, Mark E.** et al.; PAULY, DEVRIES SMITH & DEFFNER, L.L.C., 121 South 8th Street, Suite 900, MINNEAPOLIS, Minnesota 55402 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: SYSTEMS AND METHODS FOR ASSESSING THE HEALTH STATUS OF A PATIENT

(57) Abstract: Embodiments herein include medical systems, devices, and methods for assessing the health status of a patient. In an embodiment, a method includes evaluating the presence of volatile organic compounds in a breath or gas sample of the patient with a plurality of graphene sensors to generate volatile organic compound data, wherein the plurality of graphene sensors include sensors that are specific for different volatile organic compounds. The method can further include collecting data regarding the patient's sympathetic nervous activity. The method can further include combining the volatile organic compound data with the collected data regarding the patient's sympathetic nervous activity to form a combined data set. The method can further include matching the combined data set against one or more data patterns to find the best match, the best match indicating the health status of the patient. Other embodiments are also included herein.




FIG. 1



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

## SYSTEMS AND METHODS FOR ASSESSING THE HEALTH STATUS OF A PATIENT

This application is being filed as a PCT International Patent application on  
5 May 17, 2018 in the name of Cardiac Pacemakers, Inc., a U.S. national corporation,  
applicant for the designation of all countries and Gregory J. Sherwood, a U.S. Citizen,  
and Kyle Harish Srivastava, a U.S. Citizen, and Bryan Allen Clark, a U.S. Citizen,  
and Justin Theodore Nelson, a U.S. Citizen, and Carl Walter Bauer, a U.S. Citizen,  
inventors for the designation of all countries, and claims priority to U.S. Provisional  
10 Application No. 62/508,442 filed May 19, 2017, the contents of which are herein  
incorporated by reference in its entirety.

### **Field**

Embodiments herein relate to medical systems, devices and methods for  
assessing the health status of a patient.  
15

### **Background**

In the process of providing health care, clinicians often make physical  
observations and run tests to gather data about a patient. After collecting data and  
analyzing other aspects, such as a given patient's health history, the clinician often  
20 forms a diagnosis and then selects a therapy to treat the diagnosed condition.

The ability of clinicians to gather data about a patient has increased rapidly  
over time as devices, assays, and associated procedures have advanced. Yet,  
clinicians are still a long distance away from having complete health information  
about each patient. As merely one issue, the ability to gather data from or about a  
25 patient declines significantly when the patient is not in a clinical environment.  
Further, for most patients, the amount of time they spend in a clinical environment is  
relatively small compared to the time spent away from clinics, thus greatly limiting  
opportunities to gather data. Another issue is that not all disease states are fully  
characterized in terms of what pieces of data, that could be gathered, will provide  
30 diagnostic insight regarding the disease state.

While clinicians may never have complete health information about each  
patient, it is possible to increase the accuracy of health assessments and/or diagnoses  
by improving the nature and quantity of data available to clinicians.

### Summary

Embodiments herein include medical systems, devices and methods for assessing the health status of a patient.

In a first aspect, a method of assessing the health status of a patient is  
5 included. The method can include evaluating the presence of volatile organic  
compounds in a breath or gas sample of the patient with a plurality of graphene  
sensors to generate volatile organic compound data. The plurality of graphene  
sensors can include sensors that are specific for different volatile organic compounds.  
The method can further include collecting data regarding the patient's sympathetic  
10 nervous activity. The method can further include combining the volatile organic  
compound data with the collected data regarding the patient's sympathetic nervous  
activity to form a combined data set. The method can further include matching the  
combined data set against one or more previously determined data patterns using a  
pattern matching algorithm to determine the data pattern that is the best match,  
15 wherein the specific previously determined data pattern that is the best match  
indicates the health status of the patient.

In a second aspect, in addition to or in place of other aspects herein, the one or  
more previously determined data patterns are created using a machine learning  
process.

20 In a third aspect, in addition to or in place of other aspects herein, the data  
regarding the patient's sympathetic nervous activity can be selected from the group  
consisting of heart rate variability (HRV), electrodermal activity (EDA), blood  
pressure, respiratory rate, respiratory sinus arrhythmia (RSA), and baroreceptor  
sensitivity (BRS).

25 In a fourth aspect, in addition to or in place of other aspects herein, a method  
can further include collecting data regarding the patient's functional status, the data  
selected from the group consisting of gait and accelerometry data, and adding data  
regarding the patient's functional status to the combined data set.

In a fifth aspect, in addition to or in place of other aspects herein, a method  
30 can further include collecting data regarding the patient's demographic features and  
adding data regarding the patient's demographic features to the combined data set.

In a sixth aspect, in addition to or in place of other aspects herein, collecting  
data regarding the patient's sympathetic nervous activity can be performed in a non-

clinical setting and evaluating the presence of the volatile organic compounds can be performed in a clinical setting.

In a seventh aspect, in addition to or in place of other aspects herein, collecting data regarding the patient's sympathetic nervous activity can be performed with a  
5 wearable device.

In an eighth aspect, in addition to or in place of other aspects herein, collecting data regarding the patient's sympathetic nervous activity is performed over a time period of at least about 1 day.

In a ninth aspect, in addition to or in place of other aspects herein, collecting  
10 data regarding the patient's sympathetic nervous activity is performed with an implanted device.

In a tenth aspect, in addition to or in place of other aspects herein, the volatile organic compound data from the breath or gas sample of the patient is downloaded from an external breath sensing system onto at least one of a wearable device and an  
15 implantable device.

In an eleventh aspect, in addition to or in place of other aspects herein, the collected data regarding the patient's sympathetic nervous activity is uploaded from a wearable device to clinical diagnostic device.

In a twelve aspect, in addition to or in place of other aspects herein, one or  
20 more of the plurality of graphene sensors are chosen as controls on the collected data regarding the patient's sympathetic nervous activity.

In a thirteenth aspect, in addition to or in place of other aspects herein, the controls correlate with sympathetic nervous activity.

In a fourteenth aspect, in addition to or in place of other aspects herein, the  
25 method can include generating a notification if the measured values of the controls do not match the measured values of sympathetic nervous activity.

In a fifteenth aspect, in addition to or in place of other aspects herein, the collected data regarding the patient's sympathetic nervous activity reflects a baseline level of sympathetic nervous activity and changes over the baseline level of  
30 sympathetic nervous activity.

In a sixteenth aspect, in addition to or in place of other aspects herein, the plurality of graphene sensors can detect the presence of at least 10 different volatile organic compounds.

In a seventeenth aspect, a diagnostic health system is included herein. The diagnostic health system can include a communications circuit, a memory circuit, and a processor in electronic communication with the communication circuit and the memory circuit. The processor can be configured to combine volatile organic  
5 compound data with collected data regarding a patient's sympathetic nervous activity to form a combined data set. The processor can also be configured to match the combined data set against one or more previously determined data patterns using a pattern matching algorithm to determine a pattern that is the best match, wherein the specific previously determined pattern that is the best match indicates the health status  
10 of the patient. The processor can also be configured to report the health status of the patient based on the best pattern match.

In an eighteenth aspect, in addition to or in place of other aspects herein, the diagnostic health system is a wearable device and the volatile organic compound data is downloaded onto the wearable device from another device.

15 In a nineteenth aspect, in addition to or in place of other aspects herein, the diagnostic health system is disposed in a clinical environment and collected data regarding a patient's sympathetic nervous activity is uploaded to the diagnostic health system from a wearable device.

In a twentieth aspect, a diagnostic health system is included having a patient-specific device selected from the group consisting of a wearable device and an  
20 implanted device. The system can also include an external breath sensing system and a processor receiving data from the patient-specific device and the external breath sensing system. The patient-specific device can collect data regarding a patient's autonomic tone, or in some embodiments, more specifically, a patient's sympathetic  
25 nervous system activity. The external breath sensing system can collect data regarding the presence of volatile organic compounds in a breath or gas sample of the patient. The processor can be configured to combine the volatile organic compound data with the patient's sympathetic nervous activity data to form a combined data set. The processor can also be configured to match the combined data set against one or  
30 more previously determined data patterns using a pattern matching algorithm to determine a pattern that is the best match, wherein the specific previously determined pattern that is the best match indicates the health status of the patient. The processor can also be configured to report the health status of the patient based on the best pattern match.

This summary is an overview of some of the teachings of the present application and is not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details are found in the detailed description and appended claims. Other aspects will be apparent to persons skilled in the art upon  
5 reading and understanding the following detailed description and viewing the drawings that form a part thereof, each of which is not to be taken in a limiting sense. The scope herein is defined by the appended claims and their legal equivalents.

### **Brief Description of the Figures**

10 Aspects may be more completely understood in connection with the following drawings, in which:

FIG. 1 is a schematic view of various components of a system in accordance with various embodiments herein.

15 FIG. 2 is a schematic view of a patient and various devices associated with the patient.

FIG. 3 is a schematic cross-sectional view of an exemplary sensor/monitor device.

FIG. 4 is a schematic view of elements of a sensor/monitor device in accordance with various embodiments herein.

20 FIG. 5 is a schematic cross-sectional view of an implantable medical device in accordance with various embodiments herein.

FIG. 6 is a schematic view of elements of an implantable medical device in accordance with some embodiments herein.

25 FIG. 7 is a schematic cross-sectional view of elements of a gas sensing device consistent with the technology disclosed herein.

FIG. 8 is a diagram showing correspondence of various pieces of data collected from a gas sample along with various pieces of data indicative of sympathetic nervous activity.

30 FIG. 9 is a diagram showing correspondence of various pieces of data collected from a gas sample along with various pieces of data indicative of sympathetic nervous activity.

While embodiments are susceptible to various modifications and alternative forms, specifics thereof have been shown by way of example and drawings, and will be described in detail. It should be understood, however, that the scope herein is not

limited to the particular embodiments described. On the contrary, the intention is to cover modifications, equivalents, and alternatives falling within the spirit and scope herein.

5 **Detailed Description**

Volatile organic compounds, as sensed in breath samples or other gas samples, can provide valuable information about the health status of a patient. In particular, patterns of volatile organic compounds (including the presence, absence, and/or concentration of a plurality of different volatile organic compounds) in a breath or gas  
10 sample of a patient can be associated with various disease states and/or particular health statuses.

In some cases, though, the predictive power of a pattern of volatile organic compounds standing alone may have less than a desired level of accuracy. However, factors outside of the patient's breath or other gas sample can be leveraged  
15 to make the diagnostic more specific and sensitive.

Data regarding a patient's autonomic tone, or in some embodiments more specifically, a patient's sympathetic nervous system activity, can be used in combination with data regarding volatile organic compounds to enhance diagnostic specificity and/or sensitivity. For example, the onset of many illnesses are  
20 accompanied by increases in the body's sympathetic nerve activity. These changes can be detected directly or indirectly by using a number of physiological signals, including heart rate variability (HRV), electrodermal activity (EDA), factors related to the effect of sympathetic tone on vessel constriction (including, but not limited to, blood flow, perfusion, skin temperature, body temperature, blood pressure, and the  
25 like), respiratory rate, respiratory sinus arrhythmia (RSA), baroreceptor sensitivity (BRS), pupil diameter, and electrooculography. It will be appreciated that measurement of autonomic tone (e.g., parasympathetic / sympathetic balance) or measurement of parasympathetic tone can also be performed in addition to or instead of measurement of sympathetic nervous activity in some embodiments.

30 Functional signals such as gait and accelerometry can also reveal small changes in health status. Many of these signals can be easily measured in an acute setting, such as when the patient is performing the breath sensor test in the clinic. However, in some cases these signals are recorded chronically, either before or after the breath or gas sensor test. In this way, the clinician is able to obtain a mean signal. Further

details of data that can be gathered and/or used in accordance with embodiments herein are described below.

Data regarding the patient's sympathetic nervous activity can be collected over various time periods. In some embodiments, such data is collected over a time period  
5 of at least about 1 second, 5 seconds, 10 seconds, 30 seconds, 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 3 days, 5 days, 7 days, 9 days, 11 days, 13 days, 15 days, 30 days, 45 days, 60 days, 90 days, or 120 days. In some embodiments, the patient's sympathetic nervous activity can be collected over a time period in a range wherein any of the foregoing  
10 amounts of time can serve as the upper or lower bound of the range, provided that the upper bound is greater than the lower bound.

Thus, in accordance with various embodiments herein, other types of data can be combined with data regarding volatile organic compounds in order to improve the overall accuracy of assessments of the patient's health status. In particular, data  
15 regarding the sympathetic nervous state of a patient can be combined with volatile organic compound data in order to improve the accuracy of assessments of the patient's health status and/or disease state. For example, such combined data can be used to detect the signature of a medical condition. The medical condition can be any disease state including, but not limited to, lung cancer, colon cancer, pulmonary  
20 disease (e.g. asthma, COPD), cardiovascular disease (e.g. heart failure), digestive and inflammatory diseases (e.g. inflammatory bowel diseases such as Crohn's, colitis, or the like) or diabetes.

Volatile organic data can be gathered in various settings including non-clinical settings and clinical settings. Similarly, data regarding the sympathetic nervous state  
25 of a patient can be gathered in various settings including non-clinical settings and clinical settings.

In some cases, data gathered in a non-clinical setting can be combined with data gathered in a clinical setting. For example, data gathered in a clinical setting (such as breath or gas analysis data) can be downloaded to a wearable or implantable  
30 device where further operations relying upon the downloaded data can be executed by the wearable or implantable device. However, in other examples, data gathered in a non-clinical setting (such as data regarding the sympathetic nervous state of a patient) can be uploaded to a device (testing device, system or computer) in a clinical setting

and then further operations relying upon the uploaded data can be executed by the device in the clinical setting.

Referring now to FIG. 1, a schematic view is shown of possible components of a system 100 in accordance with various embodiments herein. The system 100 can include external patient specific devices within a non-clinical environment 104 (or ambulatory setting) including, but not limited to, a smart phone 106, a wearable device 108, and a patient-specific data gathering device 112, such as a weight scale. The non-clinical environment 104 can also include devices implanted within the patient 102 (discussed in greater detail with respect to FIGS. 2-3 below).

10 The non-clinical environment 104 can also include a patient communicator 110 (or patient management device). An exemplary patient management system is the LATITUDE® patient management system, commercially available from Boston Scientific Corporation, Natick, MA. Aspects of an exemplary patient management system are described in U.S. Pat. No. 6,978,182, the content of which is herein  
15 incorporated by reference.

The system 100 can also include devices within a clinical environment 120 (or non-ambulatory setting) including, but not limited to, a programmer device 124 that can be used to send data to and/or receive data from implanted devices as well as from other devices across a network.

20 The clinical environment 120 can also include a breath sensing system 160 for sensing gaseous analytes (or volatile organic compounds) in accordance with various embodiments herein. In this embodiment, the system is in a hand-held format. It will be appreciated, however, that many other formats for the system are contemplated herein.

25 The breath sensing system 160 can include a housing 178. The system 160 can include a mouthpiece 162 into which a subject to be evaluated can blow a breath sample. The system 160 can also include a display screen 174 and a user input device 176, such as a keyboard. The system can also include a gas outflow port 172. Aspects of breath sensing systems are described in U.S. Publ. Appl. No.  
30 2016/0109440, the content of which is herein incorporated by reference. While FIG. 1 shows a breath sensing system, it will be appreciated that other types of gas sampling systems can also be used herein. For example, gas sampling devices for use with catheters and endoscopy systems can also be used. An exemplary gas sampling

system in the context of a catheter or endoscopy device is described in U.S. Appl. No. 62/350,345, the content of which is herein incorporated by reference.

Devices and systems in the clinical environment 120 can communicate with devices and systems in the non-clinical environment 104 for the exchange of data.

5 Devices and systems in both the clinical environment 120 and the non-clinical environment 104 can also communicate with computing devices in remote locations through a data network 140, such as the Internet or another network for the exchange of data as packets, frames, or otherwise..

In some embodiments, the system 100 can also include a computing device such as a  
10 server 130 (real or virtual). In some embodiments, the server 130 can be located remotely from the non-clinical environment 104 and/or the clinical environment 120. The server 130 can be in data communication with a database 132.

The database 132 can be used to store various patient information, such as that described herein. In some embodiments, the database can specifically include an  
15 electronic medical database containing data regarding the health status of a patient, patterns of data associated with various conditions (such as that generated from machine learning analysis of large sets of patient data), demographic data and the like.

The server 130 can be in data communication with the non-clinical environment 104 and/or the clinical environment 120 through a network such as the  
20 Internet or another public or private data network including packet switched data networks or non-packet switched data networks. In some embodiments, the server 130 can be located in proximity to non-clinical environment 104 and/or the clinical environment 120.

As described above, FIG. 1 shows devices in a non-clinical environment 104  
25 as well as a clinical environment 120. However, it will be appreciated that some devices shown in the non-clinical environment can also be present in and used in a clinical environment. Similarly, some devices shown in the clinical environment can be present in and used in a non-clinical environment. In addition, some systems herein do not include all of the various elements shown in FIG. 1. Also, in some  
30 cases, systems herein can include additional components not shown in FIG. 1.

Referring now to FIG. 2, a schematic view is shown of patient 102 and various devices that can be associated with a patient 102. The patient 102 can have various implanted devices and/or various external devices. In specific, the patient 102 can utilize a wearable device 108. While the wearable device 108 in FIG. 2 is on the

patient's 102 wrist, it will be appreciated that this is merely one example and the device can also be worn on other parts of the patient 102. The wearable or other external devices can provide various functionality. In some embodiments, the wearable device(s) can include sensors, such as any of the types of sensors described  
5 herein. The wearable device(s) can specifically be used to gather data regarding the sympathetic nervous state of a patient (of subject).

In some embodiments, the wearable or other external device can be used to provide alerts to the patient and/or to care providers located in the same place as the patient or remotely. Alerts can take various forms. In some embodiments, the alert  
10 can be an audio and/or visual alert. In some embodiments, the wearable or other external device can be used to display information to the patient and/or to care providers. In some embodiments, the wearable or other external devices can be used to provide a prompt to the patient in order to get them to take some action in order to gather data.

Beyond external devices, there may also be implanted devices associated with the patient to gather data. For example, in some embodiments the patient 102 can have an implanted cardiac device 204. In some embodiments, the implanted cardiac device 204 can be connected to leads for sensing and/or electrical stimulation that can be disposed in or near the patient's heart 202. The implanted cardiac device 204 can  
20 include various sensors and/or can be connected to various sensors.

In some embodiments, an implanted monitoring/sensing device 206 can be implanted within the patient 102. Further details of an exemplary implanted monitoring/sensing device 206 are provided below with respect to FIG. 3 and the accompanying description. However, it will be appreciated that there are many  
25 different types of implanted devices that can be used with systems herein.

Embodiments of systems herein can include sensor/monitor devices. Referring now to FIG. 3, a schematic cross-sectional view of an exemplary sensor/monitor device 300 is shown in accordance with various embodiments herein. The sensor/monitor device 300 includes a housing 304. The housing 304 of the  
30 sensor/monitor device 300 can include various materials such as metals, polymers, ceramics, and the like. In some embodiments, the housing 304 can be a single integrated unit. In other embodiments, the housing 304 can include a main segment 313 along with appendage segments 315 and 317. In one embodiment, the housing 304, or one or more portions thereof, is formed of titanium. In some embodiments,

one or more segments of the housing 304 can be hermetically sealed. In some embodiments, the main segment 313 is formed of a metal and the appendage segments 315 and 317 are formed from a polymeric material.

The housing 304 defines an interior volume 370 that in some embodiments is  
5 hermetically sealed off from the area 372 outside of the sensor/monitor device 300. The sensor/monitor device 300 can include circuitry 351. The circuitry 351 can include various components, such as components 390, 392, 394, 396, 398, and 399. In some embodiments, these components can be integrated, and in other  
10 embodiments, these components can be separate. In some embodiments, the components can include one or more of a microprocessor, memory circuitry (such as random access memory (RAM) and/or read only memory (ROM)), recorder circuitry, telemetry circuitry, sensor and/or sensor interface circuitry, power supply circuitry (which can include one or more batteries), normalization circuitry, control circuitry, evaluation circuitry, and the like. In some embodiments, recorder circuitry can record  
15 the data produced by the various sensors and record time stamps regarding the same. In some embodiments, the circuitry can be hardwired to execute various functions while in other embodiments, the circuitry can be implemented as instructions executing on a microprocessor or other computation device.

The sensor/monitor device 300 can include, for example, an electrical field  
20 sensor that is configured to generate a signal corresponding to cardiac electric fields. The electrical field sensor can include a first electrode 382 and a second electrode 384. In some embodiments, the housing 304 itself can serve as an electrode. The electrodes can be in communication with the electrical field sensor. The electrical field sensor can include a circuit in order to measure the electrical potential difference  
25 (voltage) between the first electrode 382 and the second electrode 384. The electrical field sensor can include a circuit in order to measure the impedance between the first electrode 382 and the second electrode 384. The sensor/monitor device 300 can also include an antenna 380, to allow for unidirectional or bidirectional wireless data communication.

30 In some embodiments, the sensor/monitor device 300 can also include a chemical sensor 306. In the embodiment shown in FIG. 3, the chemical sensor can be an optical chemical sensor. However, in other embodiments, the chemical sensor can be a potentiometric chemical sensor. The chemical sensor 306 can specifically include a chemical sensing element 322, an optical window 344, and an electro-

optical module 328. The electro-optical module 328 can be in electrical communication with the circuitry 351 within the interior volume 370, and in some embodiments, the circuitry 351 is configured to selectively activate the chemical sensor 306. The chemical sensor 306 can be configured to be chronically implanted.

5           The chemical sensor 306 can include an electro-optical module 328 coupled to the optical window 344. The electro-optical module 328 can specifically include one or more optical excitation assemblies. Each optical excitation assembly can include various light sources such as light-emitting diodes (LEDs), vertical-cavity surface-emitting lasers (VCSELs), electroluminescent (EL) devices, or the like. The electro-  
10          optical module 328 can also include one or more optical detection assemblies. Each optical detection assembly can include one or more photodiodes, avalanche photodiodes, a photodiode array, a photo transistor, a multi-element photo sensor, a complementary metal oxide semiconductor (CMOS) photo sensor, or the like.

            The chemical sensing element 322 can be disposed on or over the optical  
15          window 344. The chemical sensing element 322 can be configured to detect a physiological analyte by exhibiting an optically detectable response to the physiological analyte. Specific examples of physiological analytes are discussed in greater detail below. In operation, analytes of interest from the *in vivo* environment can diffuse into the chemical sensing element 322 causing a detectable change in the  
20          optical properties of the chemical sensing element 322. Light can be generated by the electro-optical module 328 and can pass through the optical window 344 and into the chemical sensing element 322. Light can then either be preferentially reflected from or re-emitted by the chemical sensing element 322 proportional to the sensed analyte and pass back through the optical window 344 before being received by the electro-  
25          optical module 328. Various aspects of exemplary chemical sensors are described in greater detail in U.S. Pat. No. 7,809,441, the content of which is herein incorporated by reference in its entirety.

            In some embodiments the chemical sensing element 322 is located in a fluid such as blood, interstitial fluid, urine, lymph or chyle and senses analytes in the fluid.  
30          In other embodiments, the chemical sensing element 322 is located in a solid tissue such as muscle, fat, bone, bone marrow, organ tissues (e.g. kidney, liver, brain, lung, etc.) and senses analytes in the solid tissue.

            Elements of various devices (such as external wearable devices and/or implanted devices) that can be used as part of systems herein are shown in FIG. 4.

However, it will be appreciated that some embodiments devices used herein with systems can include additional elements beyond those shown in FIG. 4. In addition, some embodiments of devices used with systems herein may lack some elements shown in FIG. 4. The device 400 (which can be implanted or external) can gather  
5 information through one or more sensing channels. A microprocessor 410 can communicate with a memory 412 via a bidirectional data bus. The memory 412 can include read only memory (ROM) or random access memory (RAM) for program storage and RAM for data storage.

The device 400 can include one or more electric field sensors 422 (in some  
10 cases, electrodes) and an electric field sensor channel interface 420 (for measuring impedance, electrical potential, or other electrical properties) which can communicate with a port of microprocessor 410. The device 400 can also include one or more other sensor(s) 432 and other sensor channel interface 430 which can communicate with a port of microprocessor 410.

15 The other sensors (implantable, wearable, or non-wearable external) can include, but are not limited to, one or more of a motion sensor, a posture sensor, an activity sensor, a respiration sensor, a pressure sensor (including blood pressure and/or urine pressure), flow sensor, impedance sensor, and any of the other types of sensors discussed herein.

20 The device 400 can also include a chemical sensor 438 and a chemical sensor channel interface 436 which can communicate with a port of microprocessor 410. The sensor channel interfaces 420, 430 and 436 can include various components such as analog-to-digital converters for digitizing signal inputs, sensing amplifiers, registers which can be written to by the control circuitry in order to adjust the gain  
25 and threshold values for the sensing amplifiers, and the like. A telemetry interface (or telemetry circuit) 440 is also provided for communicating with other devices of a system such as a programmer, a home-based unit and/or a mobile unit (e.g., a cellular phone).

Data herein can also be gathered by various other types of implantable medical  
30 devices, including but not limited to implantable cardiac devices. Referring now to FIG. 5, a schematic cross-sectional view of an implantable medical device 500 is shown in accordance with various embodiments herein. The implantable medical device 500 includes a header assembly 502 and a housing 504. The housing 504 of the implantable medical device 500 can include various materials such as metals,

polymers, ceramics, and the like. In one embodiment, the housing 504 is formed of titanium. The header assembly 502 can be coupled to one or more electrical stimulation leads 550. The header assembly 502 serves to provide fixation of the proximal end of one or more leads and electrically couples the leads to components  
5 within the housing 504. The header assembly 502 can be formed of various materials including metals, polymers, ceramics, and the like.

The housing 504 defines an interior volume 570 that is hermetically sealed off from the volume 572 outside of the device 500. Various electrical conductors 509, 511 can pass from the header 502 through a feed-through structure 505, and into the  
10 interior volume 570. As such, the conductors 509, 511 can serve to provide electrical communication between the electrical stimulation lead 550 and control circuitry 551 disposed within the interior volume 570 of the housing 504. The control circuitry 551 can include various components such as a microprocessor, memory (or memory circuit) (such as random access memory (RAM) and/or read only memory (ROM)), a  
15 telemetry module, electrical field sensor and stimulation circuitry, a power supply (such as a battery), and an optical sensor interface channel, amongst others. The control circuitry 551 can include the evaluation circuitry in various embodiments herein.

The implantable medical device 500 can incorporate, for example, an  
20 electrical field sensor that is configured to generate a signal corresponding to cardiac electric fields. The electrical field sensor (for measuring impedance, electrical potential, or other electrical properties) can include a first electrode and a second electrode. The electrodes of the electrical field sensor can be the same electrodes used to provide electrical stimulation or can be different electrodes. In some  
25 embodiments, one or more electrodes can be mounted on one or more electrical stimulation leads 550. In some embodiments, the housing 504 can serve as an electrode. The electrodes can be in communication with the electrical field sensor and stimulation circuitry. The electrical field sensor can include a circuit (such as within control circuitry 551) in order to measure the electrical potential difference (voltage)  
30 between the first electrode and the second electrode. In some embodiments, the data from the electrical field sensor can be used to generate an electrocardiogram.

The implantable medical device 500 can also include a chemical sensor 506. In the embodiment shown in FIG. 5, the chemical sensor 506 is a potentiometric chemical sensor. The chemical sensor 506 can specifically include a receptor module

522, and a transducer module 528. The transducer module 528 can be in electrical communication with the circuitry 551 within the interior volume 570, and in some embodiments, the control circuitry 551 is configured to selectively activate the chemical sensor 506. The chemical sensor 506 can be configured to be chronically  
5 implanted.

The chemical sensor 506 can be configured to detect a physiological analyte by exhibiting an electrical signal response to the physiological analyte. In operation, analytes of interest from the *in vivo* environment can contact the receptor module 522 causing a detectable change in the electrical properties of the same. The transducer  
10 module 528 can then be used to process and/or propagate the signal created by the receptor module 522. While medical device 500 is described as being implantable, it will be appreciated that some or all of the same components and functionality can be included in an external and/or wearable medical device.

Elements of some embodiments of an implantable medical device that can be  
15 part of systems herein are shown in FIG. 6. However, it will be appreciated that some embodiments can include additional elements beyond those shown in FIG. 6. In addition, some embodiments may lack some elements shown in FIG. 6. The medical device 600 can sense cardiac events through one or more sensing channels and can output pacing pulses to the heart via one or more pacing channels in accordance with  
20 a programmed pacing mode. A microprocessor 610 communicates with a memory 612 via a bidirectional data bus. The memory 612 typically comprises read only memory (ROM) or random access memory (RAM) for program storage and RAM for data storage.

The implantable medical device can include atrial sensing and pacing channels  
25 comprising at least a first electrode 634, a lead 633, a sensing amplifier 631, an output circuit to provide a stimulus 632, and an atrial channel interface 630 which can communicate bidirectionally with a port of microprocessor 610. In this embodiment, the device 600 also has ventricular sensing and pacing channels comprising at least a second electrode 624, a lead 623, a sensing amplifier 621, an output circuit to provide  
30 a stimulus 622, and ventricular channel interface 620. For each channel, the same lead and electrode are used for both sensing and pacing. The channel interfaces 620 and 630 include analog-to-digital converters for digitizing sensing signal inputs from the sensing amplifiers and registers which can be written to by the control circuitry in order to output pacing pulses, change the pacing pulse amplitude, and adjust the gain

and threshold values for the sensing amplifiers. The implantable medical device 600 can also include a chemical sensor 638 and a chemical sensor channel interface 636. A telemetry interface 640 is also provided for communicating with an external programmer or another implanted medical device.

5           Systems herein can also include a breath and/or gas sensing device or system. In particular, systems herein can gather data on the presence, absence, and/or amount of various gaseous analytes including, but not limited to, volatile organic compounds. FIG. 7 is a schematic cross-sectional view of an example system 700 consistent with the technology disclosed herein. It will be appreciated that this schematic view has  
10           been simplified for ease of illustration and that embodiments of systems and devices herein can include various features not shown in FIG. 7. In addition, some embodiments of systems and devices herein may lack various features shown in FIG. 7. The system 700 is generally configured for collecting a gas sample and communicating data associated with the gas sample. The system 700 has a gas  
15           sampling device 710 and a docking station 730.

          The gas sampling device 710 can be configured to collect a gas sample and facilitate testing of the gas sample to generate data. In some embodiments, the gas sampling device 710 can be configured as a handheld device. In such cases, the gas sampling device can be configured to be held in the hand of a care provider, a patient,  
20           or both, during certain steps of its use, while also being configured to be held or otherwise positioned in association with the docking station 730 during certain steps of its use.

          In some embodiments, the gas sampling device 710 is configured to receive a gas sample, such as exhaled breath, from a patient and direct the gas sample to a  
25           testing location. The gas sampling device 710 generally has a housing 720 defining an airflow aperture 722, a gas testing chamber 726, a sensor receptacle 728, an airflow pathway 724, and a docking structure 721.

          When receiving a gas sample, the gas (such as breath from a patient), can pass into the gas sampling device 710 through the airflow aperture 722, through the airflow  
30           pathway 724, into the gas testing chamber 726 and into contact with one or more measurement zones 742 of a disposable sensor test strip 740, and then out the end of the gas testing chamber 726 through the sensor receptacle 728, or through a separate exhaust port (not shown in this view). While this view depicts contact between the sensor receptacle 728 and the disposable sensor test strip 740, it will be appreciated that

there can be segments or areas where the sensor receptacle 728 and the disposable sensor test strip 740 do not contact or do not create sealing contact, thus allowing for a path for the gas to flow out through the sensor receptacle 728.

While FIG. 7 shows the airflow pathway 724 to be approximately the same  
5 size as the interior space of the housing 720, it will be appreciated that this is simply for ease of illustration and that the size of the airflow pathway 724 can be, in many cases, much smaller than the entire interior size of the housing 720, allowing for room for other components within the interior of the housing 720, such as other components described herein including, but not limited to, sensors, a power source, processing  
10 devices, communication hardware, conditioning elements, and the like.

The housing 720 can be constructed of a variety of materials and combinations of materials. The housing 720 can be a single cohesive structure or can be constructed of multiple components that are coupled to form the housing 720. As an illustrative example, a portion of the housing 720 that defines the airflow pathway 724 can be  
15 coupled to the portion of the housing 720 that defines the airflow aperture 722. The portion of the housing 720 that defines the airflow pathway 724 can include a conduit or tube with various different cross-sectional sizes and shapes. The conduit or tube can be formed from various materials including, but not limited to, polymers, metals, ceramics, glass, composites or the like. In some embodiments, surfaces lining the  
20 airflow pathway 724 can be coated with materials to provide various desirable functional properties.

The airflow aperture 722 is generally configured to provide an input for the gas sample at the housing 720. In some embodiments the airflow aperture 722 is configured to be in fluid communication with a patient's mouth, although in some  
25 other embodiments a protective liner can be used to provide a barrier between the patient's mouth and the housing, which will be described in more detail, below.

The airflow pathway 724 generally is configured to direct the gas input at the airflow aperture 722 to the gas testing chamber 726. As such, the airflow pathway 724 generally extends from the airflow aperture 722 to the gas testing chamber 726. The  
30 airflow pathway 724 can have a cross-sectional area that is substantially the same along the length of the airflow pathway or it can vary. In some embodiments, the gas testing chamber 726 can have different interior dimensions (e.g., height, width, etc.) than the airflow pathway leading to it.

The gas testing chamber 726 defines a testing location for the gas sample. In various embodiments, the gas testing chamber 726 is configured to receive a measurement zone 742 of a disposable sensor test strip 740. Accordingly, the sensor receptacle 728 defined by the housing 720 is generally configured to removably retain the disposable sensor test strip 740 within the gas testing chamber 726. In various  
5 embodiments the sensor receptacle 728 is configured to slidably receive the disposable sensor test strip 740 that is manually inserted by a user. In some embodiments, the disposable sensor test strip 740 can be inserted with its long (or major) axis parallel to the long (or major) axis of the housing 720. However, in other  
10 embodiments, the disposable sensor test strip 740 can be inserted with its long (or major) axis positioned differently with respect to the long (or major) axis of the housing 720, such as perpendicular. Example sensor test strips will be described in more detail, below.

While FIG. 7 depicts the test strip located approximately in the middle of the gas sampling device 710 (top to bottom with regard to the perspective of the figure), it  
15 will be appreciated that the test strip can be positioned biased toward the top or the bottom, to be closer to an exterior surface of the housing 720 or gas sampling device 710. In some cases this can facilitate easier wireless reading of the disposable sensor strip by the docking station while the disposable sensor strip is still held within the  
20 housing. In some embodiments, the disposable sensor strip can be positioned less than 5 cm, 4 cm, 3 cm, 2 cm, 1 cm, 0.5 cm, 0.2 cm or less from exterior surface (or exterior wall) of the housing 720.

The docking station 730 is generally configured to collect data generated from testing the gas sample. The docking station 730 has a reading device 732 having  
25 communication hardware to wirelessly receive data through the housing of the gas sampling device 710. In many embodiments the reading device 732 of the docking station 730 is configured to wirelessly receive data from the disposable sensor test strip 740. In various embodiments, the reading device 732 can also be configured to wirelessly receive baseline data through the housing of the gas sampling device 710 –  
30 from the disposable sensor test strip 740 – where the term “baseline data” is defined as data collected before exposure of the disposable sensor test strip 740 to the gas sample or the patient or test subject. In some cases the baseline data can reflect conditions of whatever gas happens to be in the testing chamber prior to obtaining a gas sample of a patient. However, in other embodiments, ambient air can purposefully

be pushed through the testing chamber, and/or a particular reference gas sample of known composition can be put into the testing chamber for purposes of generating baseline data. The communication hardware of the reading device 732 can be capable of near field communication with the disposable sensor test strip 740. In some  
5   embodiments the communication hardware of the reading device 732 is a near field electrode or near field reading circuit that is configured to receive patient data from a passive electrical circuit, such as by detecting a resonant frequency of an LRC resonator circuit and/or changes to the same.

        In some embodiments the docking station has a proximity sensor that is  
10   configured to detect when the gas sampling device 710 is in sufficient proximity to the docking station 730 to collect data. And, although not currently depicted, in some embodiments the disposable sensor test strip 740 can have identifying information disposed thereon, other than the baseline or patient sample data, that can be read by a docking station or another device such as an identification code, radio frequency  
15   identification (RFID) tag, barcode, serial or id numbers, or other indicia. In such embodiments the docking station 730 (FIG. 7) can be configured to read, collect, save, and/or potentially transmit that identification data.

        The docking station 730 is generally configured to be a docking location for the gas sampling device 710. The docking station 730 is generally configured to  
20   physically receive the gas sampling device 710. The docking station 730 can receive the gas sampling device 710 through a variety of structures and configurations that will be appreciated by those having ordinary skill in the art. In various embodiments the docking station 730 and the docking structure 721 of the gas sampling device 710 have a mating configuration by which the docking station 730 receives the docking  
25   structure 721 of the gas sampling device 710. In some such embodiments the docking station 730 and the docking structure 721 define an interference fit. However, in other embodiments, the docking station 730 can simply rest upon or in the docking structure 721. In some embodiments the docking station 730 and the docking structure 721 are configured to position the disposable sensor test strip 740 and the reading device 732  
30   in sufficient proximity to accommodate transmission of data between the reading device 732 and disposable sensor test strip 740. In some embodiments the docking station and the docking structure are configured to position the disposable sensor test strip 740 and the reading device 732 within 6 cm, 5 cm, 4 cm, 3 cm, or 2 cm of each other, or even within 1 cm of each other.

The docking station 730 can have various additional components. In some embodiments the docking station 730 has a processor 736 and memory 735. The processor 736 and memory 735 can be configured to process and store data obtained from tested the gas sample. For example, the memory 735 can store baseline data  
5 locally and the processor 736 can be configured to remove collected baseline data from the tested gas data to obtain adjusted data. Such adjusted data can remove some impact of the ambient environment on the tested gas data. In another example, the processor can be configured to compare the adjusted data (or, in some embodiments the tested gas data) to known data indicative of one or more diseases. Such a  
10 comparison can be used to identify the presence of a particular disease using a comparative algorithm. In yet another example, the processor of the docking station 730 can be configured to identify a defect in the disposable sensor test strip 740. Example defects can include manufacturing defects and/or premature exposure to ambient gases. The docking station 730 can be configured to collect, save, and  
15 potentially transmit records of such defects.

The docking station 730 has networking hardware 734 in various embodiments. The networking hardware 734 can be configured to transmit data over a network to a remote system, including a cloud-based system. In some implementations the remote system can be a hospital, clinic, laboratory, or other  
20 location. In some embodiments the networking hardware 734 is configured to transmit data generated from testing the gas sample. The networking hardware 734 is configured to transmit baseline data in some embodiments. The networking hardware is configured to transmit adjusted data in some embodiments. In some embodiments the remote system analyzes the data it receives. For example, in some embodiments  
25 the remote system is configured to compare the adjusted data to known data indicative of a plurality of diseases. That comparison can identify the presence of a particular disease.

In some embodiments the docking station 730 has a user interface 738. The user interface 738 can be configured to communicate information to a user. For  
30 example, the user interface 738 can be configured to communicate an active data transmission, such as a data transmission between the docking station 730 and the gas sampling device 710 and/or between the docking station 730 and a network. In some embodiments the user interface 738 can be configured to communicate information about the current stage of the testing process, progress of the same, or what steps are

next or what actions are required. For example, in some cases the user interface 738 can be configured to communicate that the gas sampling device 710 is ready to receive a gas sample or that the docking station 730 has finished reading data from the gas sampling device 710. The user interface 738 can also be configured to  
5 communicate a defect in the sensor test strip. The user interface 738 can be configured to communicate through visual notification, audio notification, and the like. As a specific example, a flashing light can be used to indicate that the docking station 730 is transmitting data. The user interface 738 can include a light source such as an LED or similar light emitting device.

10 One example approach to using the system depicted in FIG. 7 will now be described. A disposable sensor test strip 740 is inserted into the gas sampling device 710 such that it is received by the gas testing chamber 726 defined by a housing of a gas sampling device. The gas sampling device 710 having the disposable sensor test strip 740 is docked to the docking station 730, and the reading device 732 of the  
15 docking station 730 reads baseline data from the disposable sensor test strip 740 through the housing 720 of the gas sampling device 710. The gas sampling device 710 is undocked from the docking station 730 after reading the baseline data, and a gas sample is received by the gas testing chamber such that the gas sample is brought into contact with the disposable sensor test strip 740. For example, the gas sampling  
20 device 710 may be physically grasped by a care provider and removed from the docking station 730 and physically handed to a patient or test subject who may then blow into the gas sampling device 710 to provide the gas sample to be analyzed. In other cases, the gas sampling device 710 may be held by the care provider instead of being held by the patient or test subject. The gas sampling device 710 can then be  
25 docked to the docking station 730 after receiving the gas sample, and the data from the tested gas is read from the disposable sensor test strip 740 by the reading device 732, wherein the adjusted data is read through the housing 720 of the gas sampling device 710. In various embodiments the disposable sensor test strip 740 is configured to be single-use. As such, the disposable sensor test strip 740 can be disposed of  
30 following the collection of sample gas data from the disposable sensor test strip 740. Various other methods of using the system depicted in FIG. 7 are also contemplated.

The measurement zones 742 can include a plurality of discrete binding detectors that can include one or more analyte binding receptors bound thereto. In some embodiments, all of the analyte binding receptors within a particular discrete

binding detector can be the same with respect to their analyte binding properties. In other embodiments, at least some of the analyte binding receptors within a particular zone can be different from one another with respect to their analyte binding properties. In some embodiments, each discrete binding detector can be unique. In some embodiments, discrete binding detectors that are unique can be cross-reactive in that they bind to different portions or different configurations of the same chemical compound. In some embodiments, each discrete binding detector can include a single passive sensor circuit. In other embodiments, each discrete binding detector can include multiple passive sensor circuits.

In some embodiments, the passive sensor circuit can include a graphene varactor (variable capacitor) or metal-graphene-oxide capacitor (wherein RS represents the series resistance and CG represents the varactor capacitor) coupled to an inductor. Graphene varactors can be prepared in various ways and with various geometries. As just one example, in some aspects, a gate electrode can be recessed into an insulator layer. A gate electrode can be formed by etching a depression into the insulator layer and then depositing an electrically conductive material in the depression to form the gate electrode. A dielectric layer can be formed on a surface of the insulator layer and the gate electrode. In some examples, the dielectric layer can be formed of a material, such as, aluminum oxide, hafnium dioxide, zirconium dioxide, hafnium silicate or zirconium silicate. A graphene layer can be disposed on the dielectric layer. In some aspects, the graphene layer can be a graphene monolayer. Contact electrodes can also be disposed on a surface of the graphene layer. Aspects of exemplary graphene varactors can be found in U.S. Publ. App. No. 2014/0145735, the content of which is herein incorporated by reference.

In various embodiments, the functionalized graphene layer (e.g., functionalized to include analyte binding receptors), which is part of the graphene varactor and thus part of a sensor circuit such as a passive sensor circuit, is exposed to the gas sample flowing over the surface of the measurement zone. The passive sensor circuit can also include an inductor. In some embodiments, only a single varactor is included with each passive sensor circuit. In other embodiments, multiple varactors are included, such as in parallel, with each passive sensor circuit.

In the passive sensor circuit, the quantum capacitance of the electrical circuit changes upon binding between the analyte binding receptors and a component from a gas sample. The passive sensor circuit can function as an LRC resonator circuit,

wherein the resonant frequency of the LRC resonator circuit changes upon binding with a component from a gas sample.

The reading circuit can be used to detect the electrical properties of the sensor circuit. By way of example, the reading circuit can be used to detect the resonant  
5 frequency of the LRC resonator circuit and/or changes in the same. In some embodiments, the reading circuit can include a reading coil having a resistance and an inductance. When the sensor-side LRC circuit is at its resonant frequency, a plot of the phase of the impedance of the reading circuit versus the frequency has a minimum (or phase dip frequency). Sensing can occur when the varactor capacitance varies in  
10 response to binding of analytes, which changes the resonant frequency, and the value of the phase dip frequency. Other techniques of reading graphene sensors can also be used.

Further aspects of gas and/or breath sampling systems are described in U.S. Publ. Appl. No. 2016/0109440, the content of which is herein incorporated by  
15 reference.

In some cases, the individual pieces of data gathered may be independent and distinct from one another. In other cases, some individual pieces of data can be associated with and/or correlated with other pieces of data and used for various purposes including, but not limited to, controls and/or validation data.

Referring now to FIG. 8, a schematic representation is shown of various pieces  
20 of data that can be combined to form a combined data set for use in later operations such as machining learning analysis and/or pattern matching. In FIG. 8, the combined data can include volatile organic compound data 802, such as that which can be generated using gas or breath sampling devices as described herein. The volatile  
25 organic compound data 802 can include a plurality of individual pieces 812 of data. The combined data can also include data regarding the patient's sympathetic nervous activity 804. It will be appreciated that in some embodiments the combined data can include any of the types of data described herein. In some embodiments, the data regarding the patient's sympathetic nervous activity 804 can include a plurality of  
30 individual pieces of data 814. In this schematic view, all of the individual pieces of data (812 and 814) are independent and distinct.

Referring now to FIG. 9, another schematic representation is shown of various pieces of data that can be combined to form a combined data set for use in later operations such as machining learning analysis and/or pattern matching. In FIG. 9,

the combined data can include volatile organic compound data 802, such as that which can be generated using gas or breath sampling devices as described herein. The volatile organic compound data 802 can include individual pieces of data 812 broke up into a first set of data 902 that is independent and distinct from other pieces  
5 of data and a second set of data 904 that is related to or correlates to certain other pieces of data, such as data regarding the patient's sympathetic nervous activity 804, or other types of data. In this manner, the first set of data 902 can be used in various ways such as a control or otherwise for validation purposes before the data is combined.

10

#### Sensors and Data

In various embodiments herein, the patient-specific device and/or other devices or systems that may be part of a system can collect data regarding a patient's autonomic tone, or in some embodiments more specifically, a patient's sympathetic  
15 nervous system activity. However, it will be appreciated that measurement of autonomic tone (e.g., parasympathetic / sympathetic balance) or measurement of parasympathetic tone can also be performed in addition to or instead of measurement of sympathetic nervous activity in some embodiments. In some embodiments other types of data can also be included such as demographic data, medical record data,  
20 measurements of environmental conditions, patient activity data, indications of symptoms, information regarding the current or past physical state of the patient, and the like.

Many different measures of sympathetic nervous activity can be gathered and/or evaluated. In some embodiments, measures of sympathetic nervous activity  
25 herein can include one or more of heart rate variability (HRV), electrodermal activity (EDA), blood pressure, respiratory rate, respiratory sinus arrhythmia (RSA), and baroreceptor sensitivity (BRS).

Many different specific sensors can be used to gather data that reflects sympathetic nervous activity. In some embodiments, an ECG sensor can be used.  
30 The ECG sensor can include at least two electrodes disposed in the patient's body configured to detect electrical activity from the patient's body. A processor circuit can use the electrogram information to identify morphological characteristics (e.g., timings, amplitudes, shapes, etc.).

Specific features from an ECG sensor can include, but are not limited to, RR interval/heart rate; P-wave detection (or a surrogate); Q-wave detection (or a surrogate); intervals between any of the features of a PQRST waveform; heart rate variability (HRV); heart rate density index of heart rate; AVNN (average of all NN intervals); SDNN (standard deviation of all NN intervals) – which is a measure of long term heart rate variability (HRV); SDANN (standard deviation of the averages of NN intervals in all 5-minute segments of a 24-hour recording) – which is a measure of long term HRV; SDNNIDX (mean of the standard deviations of NN intervals in all 5-minute segments of a 24-hour recording); RMSSD (square root of the mean of the squares of differences between adjacent NN intervals) – which is a measure of short term HRV); pNN50 (percentage of differences between adjacent NN intervals that are greater than 50 ms); power spectrum of HRV signal to determine overall spectral density in Very Low frequency (VLF) band, Low Frequency (LF) band, and High Frequency (HF) band; ratios of either two of VLF, LF, and HF bands; QRS complex amplitude or morphology, or surrogate thereof; match between ECG waveform and optimal morphology template (the optimal template can be defined and/or updated by a physician or internal algorithm based on morphology during times of good therapy), the match can be quantified using correlation between the two signals or can be quantified by when a given signal leaves an interval around the mean defined by, for example, twice the standard deviation; PP interval; PR interval; QRS azimuth; QRS duration; ST segment; QRS-T angle; QT interval; or dimensions obtained through dimensionality reduction of the entire waveform such as principal components analysis.

In some embodiments, a blood volume pulse (BVP) sensor can be used. In some embodiments, the BVP sensor can be a photoplethysmography (PPG) sensor, and the pulsatile information (including timing, shape, and morphology) can be obtained by passing light through the neighboring artery. Aspects of PPG sensors are described in U.S. Pat. No. 8,494,606 and U.S. Publ. Appl. No. 2017/0042435, the content of which is herein incorporated by reference. In some embodiments, the BVP sensor can measure externally from a finger, wrist, ear, etc. In some embodiments, the BVP sensor can measure internally near an artery. In some embodiments, the BVP sensor is an electrical bioimpedance/impedance cardiography sensor, and the pulsatile information (including timing, shape, and morphology) is obtained by measuring change in impedance across artery as blood flow changes. In some

embodiments, the BVP sensor is an accelerometer, and pulsatile information (including timing, shape, and morphology) is obtained by measuring changes in position as shape of artery changes during blood flow. In some embodiments, the BVP sensor is a pressure sensor around or nearby the artery, and the pulsatile  
5 information (including timing, shape, and morphology) is directly measured from artery. In some embodiments, the BVP sensor is a pressure sensor inside the artery, and the pulsatile information (including timing, shape, and morphology) is directly measured within the artery.

Specific features from a BVP sensor can include match between a BVP  
10 waveform and an optimal morphology template (the optimal template can be defined and/or updated by a physician or internal algorithm based on morphology during times of good therapy and a match can be quantified using correlation between the two signals or by when a given signal leaves an interval around the mean defined by, for instance, twice the standard deviation); systolic amplitude; diastolic amplitude;  
15 area under BVP waveform; pulse rate variability (calculated in any measure similar to HRV from ECG); pulse transit time; DC component of BVP waveform; AC component of BVP waveform; dicrotic notch amplitude; time between systolic and diastolic peaks; or dimensions obtained through dimensionality reduction of the entire waveform such as principal components analysis.

20 In some embodiment, an electrodermal activity (EDA) sensor can be used. Aspects of electrodermal sensors are described in U.S. Publ. Appl. No. 2017/0014043, the content of which is herein incorporated by reference. The surface electrode can measure skin conductance from, the hand (palmar surface), the foot (plantar surface), the wrist (such as incorporated into a wrist worn monitoring device),  
25 or an implanted device that is communicatively coupled to a conductive layer (tattoo) anywhere on the skin.

In some embodiments, a blood pressure sensor can be used. In various embodiments, blood pressure can be derived from heart sounds signal, a BVP signal, a blood pressure cuff, or the like.

30 In some embodiments, a respiration sensor can be used. In various embodiments, respiration can be sensed through contact based methods, through chest and abdominal movement detection, through acoustic based measures, airflow monitoring, a muscle strain sensor, or impedance based measures. Non-contact methods can also be used to detect respiration.

The respiration sensor can be an implantable sensor configured to monitor subject chest expansion and contraction. In an example, the respiration sensor can be configured to provide information about a subject's tidal volume or minute ventilation. In some embodiments, the respiration sensor can be an acoustic sensor.

5 The acoustic sensor can be an implantable transducer such as a microphone or accelerometer. The acoustic sensor can be configured to receive acoustic vibrational energy from a subject, such as in the audible spectrum. In an example, a portion of the circuitry can be configured to receive information from the acoustic sensor and identify respiration information. In some embodiments, the respiration sensor can be  
10 a vibration sensor. The vibration sensor can be an implantable transducer, such as an accelerometer. The vibration sensor can be configured to receive vibrational energy from a patient and can be used to identify respiration information. In some embodiments, the respiration sensor can be an impedance sensor configured to determine respiration data. The impedance sensor can include at least two electrodes  
15 disposed in the patient's body and configured to detect electrical signals therein. The device can be configured to receive electrical signal information from the impedance sensor to identify a detected or measured impedance between the two or more electrodes. In an example, a processor circuit can be used to process the received impedance information to identify respiration data.

20 Specific features from a respiration sensor can include absolute HRV during inspiration and expiration; ratio of HRV during inspiration to expiration; absolute HR during inspiration and expiration; and change in HR over respiration cycle.

Pulmonary data can be used in some embodiments. Pulmonary data can include forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC),  
25 FEV1/FVC, or various other lung function / spirometry test parameters. In some embodiments capnography can be used to gather data herein. In various embodiments, data indicative of a change in the pulmonary condition can be used including lung sounds, trans-thoracic impedance, vocal expression, and the like.

In some embodiments, an EEG sensor can be used. The EEG sensor can be  
30 embodied as electrodes in an EEG cap, EEG headsets, ear EEG devices, implanted subdermal wireless electrode(s) implant, implanted neuromodulation leads (e.g. occipital, trigeminal, deep brain stimulation leads), or other EEG measuring devices within sunglasses, hats, patches, etc.

In some embodiments, data from a sensor such as an electrogastrogram (EGG) can also be used. Aspects of electrogastrograms are described in U.S. Pat. No. 5,704,368, the content of which is herein incorporated by reference.

5 In some embodiments, an NIRS (near-infrared spectroscopy) sensor can be used. The NIRS sensor can be embodied as an individual NIRS optode, a multi-optode NIRS (e.g. measured using a cap, similar to EEG), a subdermal optode(s) implant. Aspects of NIRS sensors are described in U.S. Publ. Appl. No. 2014/0051956, the content of which is herein incorporated by reference.

10 EEG/NIRS features can include dominant frequency, spectral power (relative and absolute), including total power as well as individual spectral power for specific brain wave frequencies (alpha, beta, theta, etc.); coherence, cross-coherence, spectral entropy, mutual information, and other correlation measures; changes (frequency shifting) in the dominant amplitude peak for relevant frequency bands, q-factor based metrics; and other EEG/NIRS-specific metrics.

15 In some embodiments, the sensor can be an activity or gait sensor. For example, the sensor can one or more of a 3-axis accelerometer, 3-axis gyroscope, and/or 3-axis magnetometer. In some embodiments, the sensor can be an electromyography (EMG) sensor.

20 Baroreceptor reflex sensitivity (BRS) features can be calculated using measures such as blood pressure; heart rate or inter-beat Interval (IBI); heart rate variability; change in heart rate – captured as a slope of change or as a time interval for the parameter to reach X % of the peak change; change in blood pressure – captured as a slope of change or as a time interval for the parameter to reach X % of the peak change. BRS can be classified based on the level of physical activity or exertion indicated by the activity and respiration sensors (e.g., mild activity, moderate activity, or vigorous activity). BRS can be characterized over a continuum of levels of physical activity or exertion indicated by the activity and respiration signals, for example, by vector magnitude units (in g) over a period of time, caloric expenditure, distance traveled, or other activity or exertion measures, or a combination thereof.

30 Aspects from medical records can also be used as data herein. Examples of such data include, but are not limited to, medication information, previous symptoms, previous diagnoses, previously obtained diagnostic test results, previous medical procedures performed on the patient, and the like.

Data herein can include sleep data. Sleep data can include, but is not limited to, average sleep duration, REM sleep cycles and durations, sleep quality, activity during sleep, sleep apnea incidents, breathing patterns during sleep, waking episodes, morning waking time, and the like.

5 In addition to other types of data described herein, in some embodiments demographic features from patient can be used, including but not limited to, age, sex, geography, and/or ethnicity. Other types of data can include the time of day when measurements are taken.

In some embodiments, external environmental condition data can also be used.  
10 Environmental condition data can include, but is not limited to, humidity, external temperature, current weather, pollution level and the like.

In some embodiments, data regarding the patient's use of, or irregular patterns regarding, the Internet, social media, Internet searches, and the like can be used.

## 15 Methods

Embodiments herein can include various methods. Exemplary methods can include any of the approaches and/or operations described herein. In an embodiment, a method of assessing the health status of a patient is included. The method can include evaluating the presence of volatile organic compounds in a breath or gas  
20 sample of the patient to generate volatile organic compound data. The volatile organic compound data can be gathered using systems and devices such as those described herein.

In some cases, the volatile organic compound data can reflect the output of a plurality of graphene sensors. The plurality of graphene sensors can include sensors  
25 that are specific for different volatile organic compounds. In some embodiments, the plurality of graphene sensors can detect the presence of at least 5, 10, 15, 20, 30, 40 or more different volatile organic compounds. In some embodiments, the number of different volatile organic compounds detected by the graphene sensors can be in a range wherein any of the forgoing numbers can serve as the upper or lower bound of  
30 the range provided that the upper bound is greater than the lower bound.

In some embodiments, one or more of the plurality of graphene sensors are chosen as controls on the collected data regarding the patient's sympathetic nervous activity. In some embodiments, the controls correlate with sympathetic nervous activity. In some embodiments, the method can include generating a notification if the

measured values of the controls do not match what would be expected for the measured values of sympathetic nervous activity.

The method can further include collecting data regarding the patient's sympathetic nervous activity. In specific, the data regarding the patient's sympathetic nervous activity can include changes in the patient's sympathetic nervous activity and/or trends regarding the same. Sympathetic nervous activity can be gathered in either a clinical or a non-clinical environment. In some embodiments, data regarding the patient's sympathetic nervous activity can be gathered using a wearable device and/or an implanted device. In some embodiments, the collected data regarding the patient's sympathetic nervous activity reflects a baseline level of sympathetic nervous activity and changes over the baseline level of sympathetic nervous activity.

Many different types of data that reflect a patient's sympathetic nervous activity can be used. However, in some embodiments, the data regarding the patient's sympathetic nervous activity can be selected from the group consisting of heart rate variability (HRV), electrodermal activity (EDA), blood pressure, respiratory rate, respiratory sinus arrhythmia (RSA), and baroreceptor sensitivity (BRS).

In some embodiments, data regarding the patient's sympathetic nervous activity can be gathered over a period of time. In some embodiments, collecting data regarding the patient's sympathetic nervous activity is performed over a time period of at least about 1 second, 5 seconds, 10 seconds, 15 seconds, 30 seconds, 60 seconds, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 20 days, 30 days, 45 days, 60 days, 90 days, 120 days or more. In some embodiments, the data can be collected over a time period in a range wherein any of the foregoing times can serve as the upper or lower bound of the range, provided that the upper bound is greater than the lower bound. While not intending to be bound by theory, it is believed that the longer the duration, the more data will exist on the patient's baseline state and the better the ability to detect or predict any excursion from the baseline state.

Regardless of where the data is gathered, in many embodiments, the data can be exchanged with other devices and/or other components of a system. In some embodiments, the volatile organic compound data from a breath sample of the patient is downloaded onto at least one of a wearable device and an implantable device from an external breath testing device. In some embodiments, collected data regarding the

patient's sympathetic nervous activity is uploaded from a wearable device to clinical diagnostic device.

The method can further include combining the volatile organic compound data with the collected data regarding the patient's sympathetic nervous activity to form a  
5 combined data set. In some cases, all pieces of data in the combined data set can be weighted equally. In other cases, some of the pieces of data in the combined data set can be weighted more heavily than others. In some embodiments, some pieces of data may simply serve as a control.

It will be appreciated that although the combined data set frequently includes  
10 volatile organic compound data and data regarding the patient's sympathetic nervous state, still other types of data can be added into the combined data set, such as other types of data described herein. For example, in some embodiments the method can also include collecting data regarding the patient's functional status. The data regarding the patient's functional status can be selected from the group consisting of  
15 gait and accelerometry data. In some embodiments, the method can also include adding the data regarding the patient's functional status to the combined data set.

The method can further include comparing the combined data set against one or more previously determined patterns using a pattern matching or pattern  
20 recognition algorithm to determine the pattern that is the best match, wherein the specific previously determined pattern that is the best match indicates the health status of the patient.

By way of example, patterns amongst large sets of patient data may be originally identified through machine learning analysis or another similar algorithmic technique. For example, a training set of data including: 1.) information regarding  
25 volatile organic compounds for a set of patients, 2.) information regarding sympathetic nervous state or activity for the same set of patients, 3.) information regarding specific diagnoses or other health statuses for the same set of patients, and/or 4.) other types of data described herein can be processed with a machine learning algorithm or similar algorithmic technique in order to generate one or more  
30 patterns of volatile organic compounds, sympathetic nervous state, and/or other data that correlate with certain diagnosis or health statuses.

Algorithms can be used to create new models using any of numerous machine learning techniques, or apply the results of previously calculated models using these techniques, such as logistic regression; random forest, or an artificial neural network,

Many different pattern matching or pattern recognition algorithms can be used. By way of example, in some embodiments a least squares algorithm can be used to identify a particular pre-determined pattern that a combined data set most closely matches.

5 In some embodiments, the patient can be prompted to take a breath or gas test (where the test could be performed either in a non-clinical setting such as their home or where such a prompt could cause them to come to a clinical setting to take the test).

In some embodiments, a pattern including such things as sleep patterns (e.g. wearable, implant or non-contact in-home sensor), physiological data (autonomic tone  
10 measures), body weight (such as weight automatically measured by a mat in the house), activity levels (e.g. mobile device, wearable, implant or non-contact in-home sensor), etc. can be assessed, such as using an algorithm, and if the results of those factors so indicate, then the system can inform the user that they should administer or get a breath or gas test to detect early signs of heart failure decompensation. If a  
15 positive result, or data trends are beyond a normal range for the individual patient, then the system can inform the patient to seek medical care for early intervention.

In some embodiments, a pattern including things such as sleep patterns, autonomic tone, respiratory rate, respiratory sounds, activity levels, etc., can be used to recommend to the user that they should administer a breath test (or come to a clinic  
20 to get a breath test) to detect early signs of a COPD exacerbation or repeat exacerbation. If a positive result, or data trends beyond normal range for the individual patient, seek medical care and/or use prescribed pharmaceutical (e.g. bronchodilators, corticosteroids, etc.) for early intervention.

Beyond, heart failure decompensation and COPD, such patterns and prompts  
25 to the patient to get a breath test can also be used for diabetes management and inflammatory bowel diseases (also including data regarding dietary intake, autonomic tone, etc. in the pattern) to detect early signs of a flare-up.

It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content  
30 clearly dictates otherwise. Thus, for example, reference to a composition containing "a compound" includes a mixture of two or more compounds. It should also be noted that the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise.

It should also be noted that, as used in this specification and the appended claims, the phrase “configured” describes a system, apparatus, or other structure that is constructed or configured to perform a particular task or adopt a particular configuration to. The phrase "configured" can be used interchangeably with other  
5 similar phrases such as arranged and configured, constructed and arranged, constructed, manufactured and arranged, and the like. “Circuitry” can include both hardwired circuitry for execution of particular operations as well as processors that are programmed to execute instructions to provide the same functionality.

All publications and patent applications in this specification are indicative of  
10 the level of ordinary skill in the art to which this specification pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated by reference.

Aspects have been described with reference to various specific and preferred  
15 embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope herein. As such, the embodiments described herein are not intended to be exhaustive or to limit the scope to the precise forms disclosed herein. Rather, the embodiments are chosen and described so that others skilled in the art can appreciate and understand  
20 the principles and practices.

**The Claims Are:**

1. A method of assessing the health status of a patient comprising:
  - evaluating the presence of volatile organic compounds in a breath or gas sample of the patient with a plurality of graphene sensors to generate volatile organic compound data, wherein the plurality of graphene sensors include sensors that are specific for different volatile organic compounds;
  - collecting data regarding the patient's sympathetic nervous activity;
  - combining the volatile organic compound data with the collected data regarding the patient's sympathetic nervous activity to form a combined data set; and
  - matching the combined data set against one or more previously determined data patterns using a pattern matching algorithm to determine the data pattern that is the best match, wherein the specific previously determined data pattern that is the best match indicates the health status of the patient.
  
2. The method of any of claims 1 and 3-12, wherein the one or more previously determined data patterns are created using a machine learning process.
  
3. The method of any of claims 1-2 and 4-12, the data regarding the patient's sympathetic nervous activity selected from the group consisting of heart rate variability (HRV), electrodermal activity (EDA), blood pressure, respiratory rate, respiratory sinus arrhythmia (RSA), and baroreceptor sensitivity (BRS).
  
4. The method of any of claims 1-3 and 5-12, further comprising
  - collecting data regarding the patient's functional status, the data selected from the group consisting of gait and accelerometry data; and
  - adding data regarding the patient's functional status to the combined data set.
  
5. The method of any of claims 1-4 and 6-12, further comprising
  - collecting data regarding the patient's demographic features; and
  - adding data regarding the patient's demographic features to the combined data set.

6. The method of any of claims 1-5 and 7-12, wherein collecting data regarding the patient's sympathetic nervous activity is performed in a non-clinical setting and evaluating the presence of the volatile organic compounds is performed in a clinical setting.

7. The method of any of claims 1-6 and 8-12, wherein collecting data regarding the patient's sympathetic nervous activity is performed with a wearable device.

8. The method of any of claims 1-7 and 9-12, wherein collecting data regarding the patient's sympathetic nervous activity is performed over a time period of at least about 1 day.

9. The method of any of claims 1-8 and 10-12, wherein collecting data regarding the patient's sympathetic nervous activity is performed with an implanted device.

10. The method of any of claims 1-9 and 11-12, wherein the volatile organic compound data from the breath or gas sample of the patient is downloaded from an external breath sensing system onto at least one of a wearable device and an implantable device.

11. The method of any of claims 1-10 and 12, wherein the collected data regarding the patient's sympathetic nervous activity is uploaded from a wearable device to clinical diagnostic device.

12. The method of any of claims 1-11, wherein one or more of the plurality of graphene sensors are chosen as controls on the collected data regarding the patient's sympathetic nervous activity, wherein the controls correlate with sympathetic nervous activity.

13. A diagnostic health system comprising:

a communications circuit;

a memory circuit; and

a processor in electronic communication with the communication circuit and the memory circuit, the processor is configured to

combine volatile organic compound data with collected data regarding a patient's sympathetic nervous activity to form a combined data set; and

match the combined data set against one or more previously determined data patterns using a pattern matching algorithm to determine a pattern that is the best match, wherein the specific previously determined pattern that is the best match indicates the health status of the patient; and

report the health status of the patient based on the best pattern match.

14. The diagnostic health system of claim 13, wherein the diagnostic health system is disposed in a clinical environment and collected data regarding a patient's sympathetic nervous activity is uploaded to the diagnostic health system from a wearable device.

15. A diagnostic health system comprising:

a patient-specific device selected from the group consisting of a wearable device and an implanted device; and

an external breath sensing system; and

a processor receiving data from the patient-specific device and the external breath sensing system;

wherein the patient-specific device collects data regarding a patient's sympathetic nervous activity;

wherein the external breath sensing system collects data regarding the presence of volatile organic compounds in a breath or gas sample of the patient; and

wherein the processor is configured to

combine the volatile organic compound data with the patient's sympathetic nervous activity data to form a combined data set; and

match the combined data set against one or more previously determined data patterns using a pattern matching algorithm to determine a pattern that is the best match, wherein the specific previously determined pattern that is the best match indicates the health status of the patient; and

report the health status of the patient based on the best pattern match.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9

INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2018/033166

A. CLASSIFICATION OF SUBJECT MATTER  
 INV. A61B5/00 A61B5/021 A61B5/024 A61B5/08  
 ADD.  
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
 Minimum documentation searched (classification system followed by classification symbols)  
 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2017/053068 A1 (PILLAI DANA S [US] ET AL) 23 February 2017 (2017-02-23) paragraphs [0164], [0325], [0326], [0330], [0331], [0332], [0351], [0352], [0359]	1-15
X	US 2013/211852 A1 (ROIZEN MICHAEL F [US] ET AL) 15 August 2013 (2013-08-15) paragraphs [0019] - [0021]	1-15
X	JP 2011 102747 A (KITAKYUSHU FOUNDATION) 26 May 2011 (2011-05-26) paragraphs [0016], [0022], [0025], [0029]	1-15
	----- -/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>
---	---

Date of the actual completion of the international search <b>21 September 2018</b>	Date of mailing of the international search report <b>02/10/2018</b>
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <b>Knüpling, Moritz</b>
--	---

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2018/033166

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KUMUD MALIKA TRIPATHI ET AL: "Recent advances in engineered graphene and composites for detection of volatile organic compounds (VOCs) and non-invasive diseases diagnosis", CARBON., vol. 110, 1 December 2016 (2016-12-01), pages 97-129, XP055448434, GB ISSN: 0008-6223, DOI: 10.1016/j.carbon.2016.08.040 abstract -----</p>	1-15

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2018/033166
---

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2017053068	A1	23-02-2017	AU 2015223112 A1 05-05-2016
			CA 2940766 A1 03-09-2015
			CN 106462913 A 22-02-2017
			EP 3111411 A1 04-01-2017
			US 2017053068 A1 23-02-2017
			US 2017068782 A1 09-03-2017
			WO 2015130786 A1 03-09-2015
-----			
US 2013211852	A1	15-08-2013	US 2013211852 A1 15-08-2013
			WO 2013123190 A1 22-08-2013
-----			
JP 2011102747	A	26-05-2011	JP 5652847 B2 14-01-2015
			JP 2011102747 A 26-05-2011
-----			

专利名称(译)	评估患者健康的系统和方法		
公开(公告)号	<a href="#">EP3624678A1</a>	公开(公告)日	2020-03-25
申请号	EP2018731579	申请日	2018-05-17
[标]申请(专利权)人(译)	波士顿科学西美德公司		
申请(专利权)人(译)	BOSTON SCIENTIFIC SCIMED INC.		
当前申请(专利权)人(译)	BOSTON SCIENTIFIC SCIMED INC.		
[标]发明人	SHERWOOD GREGORY J SRIVASTAVA KYLE HARISH CLARK BRYAN ALLEN NELSON JUSTIN THEODORE		
发明人	SHERWOOD, GREGORY J. SRIVASTAVA, KYLE HARISH CLARK, BRYAN ALLEN NELSON, JUSTIN THEODORE BAUER, CARL WALTER		
IPC分类号	A61B5/00 A61B5/021 A61B5/024 A61B5/08		
CPC分类号	A61B5/021 A61B5/02405 A61B5/0816 A61B5/082 A61B5/681 A61B5/686 A61B5/7264 A61B5/0022 A61B5/0205 A61B5/7275 G16H10/65 G16H50/20 G16H50/30		
优先权	62/508442 2017-05-19 US		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

本文的实施例包括用于评估患者的健康状况的医疗系统，设备和方法。在一个实施例中，一种方法包括使用多个石墨烯传感器评估患者的呼吸或气体样本中挥发性有机化合物的存在以生成挥发性有机化合物数据，其中多个石墨烯传感器包括对不同挥发性具有特异性的传感器。有机化合物。该方法可以进一步包括收集关于患者的交感神经活动的数据。该方法可以进一步包括将挥发性有机化合物数据与所收集的关于患者的交感神经活动的数据进行组合以形成组合的数据集。该方法可以进一步包括将组合的数据集与一个或多个数据模式进行匹配以找到最佳匹配，最佳匹配指示患者的健康状况。本文还包括其他实施例。